Regarding biological mechanisms, even transient antiangiogenic therapy induced sustained hypoxia and other changes in the tumor microenvironment [13,14,15], and induction treatment with anti-VEGF therapy has been described in association with resistance to cetuximab [11,12]. Here, VEGFA is linked to neoplasm.